Povorcitinib

Generic Name: Povorcitinib

Clinical Trials

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

Phase 2

Active, not recruiting

Conditions: Urticaria
Hives
Angioedema
Pruritis
Chronic Spontaneous Urticaria
Chronic Idiopathic Urticaria

Interventions: Drug: Povorcitinib
Drug: Placebo

First Posted Date: 2023-07-07

Last Posted Date: 2025-04-03

Lead Sponsor: Incyte Corporation

Target Recruit Count: 136

Registration Number: NCT05936567

Locations: 🇺🇸
Clinical Research Center of Alabama, Birmingham, Alabama, United States
🇺🇸
Cahaba Dermatology, Birmingham, Alabama, United States
🇺🇸
Foothills Research Center, Scottsdale, Arizona, United States

and more 39 locations

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Phase 2

Recruiting

Conditions: Moderate to Severe Asthma

Interventions: Drug: povorcitinib
Other: placebo
Drug: ICS-LABA

First Posted Date: 2023-05-09

Last Posted Date: 2025-05-09

Lead Sponsor: Incyte Corporation

Target Recruit Count: 240

Registration Number: NCT05851443

Locations: 🇦🇷
Centro Medico Dharma, Mendoza, Argentina
🇯🇵
Idaimae Minami Yojo Int Clinic, Sapporo, Japan
🇯🇵
Tokyo Shinagawa Hospital, Shinagawa-ku, Japan

and more 81 locations

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

Phase 1

Completed

Conditions: Kidney Diseases
Renal Insufficiency

Interventions: Drug: INCB054707

First Posted Date: 2022-11-22

Last Posted Date: 2024-02-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 43

Registration Number: NCT05624723

Locations: 🇩🇪
Apex Gmbh, Munich, Germany
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Phase 1

Completed

Conditions: Renal Insufficiency
Kidney Diseases

Interventions: Drug: INCB054707

First Posted Date: 2022-11-22

Last Posted Date: 2024-04-09

Lead Sponsor: Incyte Corporation

Target Recruit Count: 25

Registration Number: NCT05624710

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Texas Liver Institute Tli the Liver Institute of South Texas List Downtown Office, San Antonio, Texas, United States

and more 1 locations

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Active, not recruiting

Conditions: Hidradenitis Suppurativa (HS)

Interventions: Drug: Povorcitinib
Drug: Placebo

First Posted Date: 2022-11-17

Last Posted Date: 2025-03-25

Lead Sponsor: Incyte Corporation

Target Recruit Count: 608

Registration Number: NCT05620823

Locations: 🇺🇸
Investigative Site US303, Phoenix, Arizona, United States
🇺🇸
Investigative Site US335, Arkansas, Arkansas, United States
🇺🇸
Investigative Site US315, Laguna Niguel, California, United States

and more 101 locations

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Phase 3

Active, not recruiting

Conditions: Hidradenitis Suppurativa (HS)

Interventions: Drug: Povorcitinib
Drug: Placebo

First Posted Date: 2022-11-17

Last Posted Date: 2025-03-26

Lead Sponsor: Incyte Corporation

Target Recruit Count: 619

Registration Number: NCT05620836

Locations: 🇺🇸
Investigative Site US240, Scottsdale, Arizona, United States
🇺🇸
Investigative Site US237, Scottsdale, Arizona, United States
🇺🇸
Investigative Site US214, Arkansas, Arkansas, United States

and more 98 locations

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: INCB054707
Drug: Placebo

First Posted Date: 2021-10-05

Last Posted Date: 2022-09-16

Lead Sponsor: Incyte Biosciences Japan GK

Target Recruit Count: 30

Registration Number: NCT05068466

Locations: 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

Phase 2

Completed

Conditions: Prurigo Nodularis

Interventions: Drug: INCB054707
Drug: Placebo

First Posted Date: 2021-09-29

Last Posted Date: 2024-08-29

Lead Sponsor: Incyte Corporation

Target Recruit Count: 146

Registration Number: NCT05061693

Locations: 🇺🇸
Investigative Site US016, Miami, Florida, United States
🇵🇱
Investigative Site PL004, Torun, Poland
🇺🇸
Investigative Site US010, Phoenix, Arizona, United States

and more 46 locations

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

Phase 2

Completed

Conditions: NonSegmental Vitiligo

Interventions: Drug: Placebo
Drug: INCB054707

First Posted Date: 2021-03-26

Last Posted Date: 2024-04-11

Lead Sponsor: Incyte Corporation

Target Recruit Count: 171

Registration Number: NCT04818346

Locations: 🇺🇸
Investigative Site 027, Verona, New Jersey, United States
🇺🇸
Investigative Site 011, West Palm Beach, Florida, United States
🇺🇸
Investigative Site 024, Covington, Louisiana, United States

and more 28 locations

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Phase 2

Completed

Conditions: Hidradenitis Suppurativa
Acne Inversa

Interventions: Drug: INCB054707
Drug: Placebo

First Posted Date: 2020-07-17

Last Posted Date: 2023-09-28

Lead Sponsor: Incyte Corporation

Target Recruit Count: 209

Registration Number: NCT04476043

Locations: 🇺🇸
Investigative Site 018, Bellaire, Texas, United States
🇩🇪
Investigative Site 403, Berlin, Germany
🇩🇪
Investigative Site 401, Bochum, Germany

and more 37 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy